{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T12:46:51Z","timestamp":1784292411137,"version":"3.55.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T00:00:00Z","timestamp":1695945600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T00:00:00Z","timestamp":1695945600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Ningbo Public welfare project","award":["2019C50071"],"award-info":[{"award-number":["2019C50071"]}]},{"name":"Ningbo Social and Development project","award":["2016C51018"],"award-info":[{"award-number":["2016C51018"]}]},{"name":"Yinzhou District Social and Development project","award":["YZ2017-59"],"award-info":[{"award-number":["YZ2017-59"]}]},{"name":"Zhejiang Medical Health Science and Technology Project","award":["2023KY1143"],"award-info":[{"award-number":["2023KY1143"]}]},{"name":"Ningbo Medical & Health Leading Academic Discipline Project","award":["2022-S05"],"award-info":[{"award-number":["2022-S05"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s00277-023-05469-y","type":"journal-article","created":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T07:01:47Z","timestamp":1695970907000},"page":"3567-3573","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effectiveness of single-dose 6 mg pegfilgrastim in mobilizing peripheral blood stem cells in allogeneic hematopoietic cell transplantation donors"],"prefix":"10.1007","volume":"102","author":[{"given":"Junjie","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5570-9007","authenticated-orcid":false,"given":"Aizhen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renzhi","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuhui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangyue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peipei","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,29]]},"reference":[{"key":"5469_CR1","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1182\/blood.V85.6.1666","volume":"85","author":"N Schmitz","year":"1995","unstructured":"Schmitz N, Dreger P, Suttorp M et al (1995) Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor). Blood 85:1666\u20131672. https:\/\/doi.org\/10.1182\/blood.V85.6.1666","journal-title":"Blood"},{"key":"5469_CR2","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1080\/10428190290033323","volume":"43","author":"N Kr\u00f6ger","year":"2002","unstructured":"Kr\u00f6ger N, Zander AR (2002) Dose and schedule effect of G-GSF for stem cell mobilization in healthy donors for allogeneic transplantation. Leuk Lymphoma 43:1391\u20131394. https:\/\/doi.org\/10.1080\/10428190290033323","journal-title":"Leuk Lymphoma"},{"key":"5469_CR3","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.2165\/00003495-200262080-00012","volume":"62","author":"MP Curran","year":"2002","unstructured":"Curran MP, Goa KL (2002) Pegfilgrastim. Drugs 62:1207\u20131213; discussion 1214-5. https:\/\/doi.org\/10.2165\/00003495-200262080-00012","journal-title":"Drugs"},{"key":"5469_CR4","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1177\/1078155217714859","volume":"24","author":"TC Bond","year":"2018","unstructured":"Bond TC, Szabo E, Gabriel S et al (2018) Meta-analysis and indirect treatment comparison of lipegfilgrastim with pegfilgrastim and filgrastim for the reduction of chemotherapy-induced neutropenia-related events. J Oncol Pharm Pract 24:412\u2013423. https:\/\/doi.org\/10.1177\/1078155217714859","journal-title":"J Oncol Pharm Pract"},{"key":"5469_CR5","doi-asserted-by":"publisher","first-page":"9317","DOI":"10.1007\/s00520-022-07353-3","volume":"30","author":"H Link","year":"2022","unstructured":"Link H, Thompson SF, Tian M et al (2022) A comparative assessment of neutropenia events, healthcare resource use, and costs among cancer patients treated with lipegfilgrastim compared with pegfilgrastim in Germany. Support Care Cancer 30:9317\u20139327. https:\/\/doi.org\/10.1007\/s00520-022-07353-3","journal-title":"Support Care Cancer"},{"key":"5469_CR6","doi-asserted-by":"publisher","first-page":"70","DOI":"10.3760\/cma.j.issn.0253-2727.2021.01.014","volume":"42","author":"T Wang","year":"2021","unstructured":"Wang T, Feng R, Li JT et al (2021) Application of pegylated recombinant human granulocyte colony stimulating factor in mobilization of autologous peripheral blood stem cells. Zhonghua Xue Ye Xue Za Zhi 42:70\u201373. https:\/\/doi.org\/10.3760\/cma.j.issn.0253-2727.2021.01.014","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"5469_CR7","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s00508-017-1205-z","volume":"129","author":"B Skopec","year":"2017","unstructured":"Skopec B, Skerget M, Zontar D et al (2017) Filgrastim-alone versus pegylated filgrastim-alone for autologous peripheral blood stem cells mobilization in newly diagnosed multiple myeloma patients. Wien Klin Wochenschr 129:545\u2013551. https:\/\/doi.org\/10.1007\/s00508-017-1205-z","journal-title":"Wien Klin Wochenschr"},{"key":"5469_CR8","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1007\/s00277-019-03800-0","volume":"99","author":"X Ding","year":"2020","unstructured":"Ding X, Huang W, Peng Y et al (2020) Pegfilgrastim improves the outcomes of mobilization and engraftment in autologous hematopoietic stem cell transplantation for the treatment of multiple myeloma. Ann Hematol 99:1331\u20131339. https:\/\/doi.org\/10.1007\/s00277-019-03800-0","journal-title":"Ann Hematol"},{"key":"5469_CR9","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.bbmt.2006.03.001","volume":"12","author":"GR Hill","year":"2006","unstructured":"Hill GR, Morris ES, Fuery M et al (2006) Allogeneic stem cell transplantation with peripheral blood stem cells mobilized by pegylated G-CSF. Biol Blood Marrow Transplant 12:603\u2013607. https:\/\/doi.org\/10.1016\/j.bbmt.2006.03.001","journal-title":"Biol Blood Marrow Transplant"},{"key":"5469_CR10","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s12185-014-1507-0","volume":"99","author":"C Chanswangphuwana","year":"2014","unstructured":"Chanswangphuwana C, Kupatawintu P, Panjai P, Tunsittipun P, Intragumtornchai T, Bunworasate U (2014) Successful peripheral blood stem cell mobilization using pegfilgrastim in allogeneic stem cell transplantation. Int J Hematol 99:18\u201322. https:\/\/doi.org\/10.1007\/s12185-014-1507-0","journal-title":"Int J Hematol"},{"key":"5469_CR11","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events v5.0. https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/CTCAE_v5.0.xlsx. NIH November 27, 2017"},{"key":"5469_CR12","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13045-019-0710-0","volume":"12","author":"K Wang","year":"2019","unstructured":"Wang K, Lv M, Chang YJ et al (2019) Early myeloid-derived suppressor cells (HLA-DR-\/low CD33+ CD16-) expanded by granulocyte colony-stimulating factor prevent acute graft-versus-host disease (GVHD) in humanized mouse and might contribute to lower GVHD in patients post allo-HSCT. J Hematol Oncol 12:31\u201346. https:\/\/doi.org\/10.1186\/s13045-019-0710-0","journal-title":"J Hematol Oncol"},{"key":"5469_CR13","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1053\/j.seminoncol.2004.04.002","volume":"31","author":"L Biganzoli","year":"2004","unstructured":"Biganzoli L, Untch M, Skacel T et al (2004) Neulasta (pegfilgrastim): a once-per-cycle option for the management of chemotherapy-induced neutropenia. Semin Oncol 31:27\u201334. https:\/\/doi.org\/10.1053\/j.seminoncol.2004.04.002","journal-title":"Semin Oncol"},{"key":"5469_CR14","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.transci.2015.03.017","volume":"53","author":"JW Kuan","year":"2015","unstructured":"Kuan JW, Su AT, Wong SP et al (2015) A randomized double blind control trial comparing filgrastim and pegfilgrastim in cyclophosphamide peripheral blood hematopoietic stem cell mobilization. Transfus Apher Sci 53:196\u2013204. https:\/\/doi.org\/10.1016\/j.transci.2015.03.017","journal-title":"Transfus Apher Sci"},{"key":"5469_CR15","doi-asserted-by":"publisher","unstructured":"Simona B, Cristina R (2010) Luca N, et al, A single dose of pegfilgrastim versus daily filgrastim to evaluate the mobilization and the engraftment of autologous peripheral hematopoietic progenitors in malignant lymphoma patients candidate for high-dose chemotherapy. 43:321\u2013326. https:\/\/doi.org\/10.1016\/j.transci.2010.10.001","DOI":"10.1016\/j.transci.2010.10.001"},{"key":"5469_CR16","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1016\/s0301-472x(99)00112-5","volume":"27","author":"G Molineux","year":"1999","unstructured":"Molineux G, Kinstler O, Briddell B et al (1999) A new form of filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans. Exp Hematol 27:1724\u20131734. https:\/\/doi.org\/10.1016\/s0301-472x(99)00112-5","journal-title":"Exp Hematol"},{"key":"5469_CR17","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1007\/s12185-014-1507-0","volume":"99","author":"C Chanswangphuwana","year":"2014","unstructured":"Chanswangphuwana C, Kupatawintu P, Panjai P et al (2014) Successful peripheral blood stem cell mobilization using pegfilgrastim in allogeneic stem cell transplantation. Int J Hematol 99:318\u2013322. https:\/\/doi.org\/10.1007\/s12185-014-1507-0","journal-title":"Int J Hematol"},{"key":"5469_CR18","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1016\/j.exphem.2005.08.003","volume":"90","author":"F Kroschinsky","year":"2005","unstructured":"Kroschinsky F, H\u00f6lig K, Poppe-Thiede K et al (2005) Single-dose pegfilgrastim for the mobilization of allogeneic CD34+peripheral blood progenitor cells in healthy family and unrelated donors. Haematologica 90:1665\u20131671. https:\/\/doi.org\/10.1016\/j.exphem.2005.08.003","journal-title":"Haematologica"},{"key":"5469_CR19","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.3389\/fonc.2020.01598","volume":"3","author":"JL Li","year":"2020","unstructured":"Li JL, Wang SB, Zhang YC et al (2020) Is it better to mobilize hematopoietic stem cells with pegfilgrastim in healthy donors during allogeneic hematopoietic stem cell transplantation? Front Oncol 3:1598. https:\/\/doi.org\/10.3389\/fonc.2020.01598","journal-title":"Front Oncol"},{"key":"5469_CR20","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1111\/j.1537-2995.2006.00699.x","volume":"46","author":"I Bruns","year":"2006","unstructured":"Bruns I, Steidl U, Kronenwett R et al (2006) A single dose of 6 or 12 mg of pegfilgrastim for peripheral blood progenitor cell mobilization results in similar yields of CD34+ progenitors in patients with multiple myeloma. Transfusion 46:180\u2013185. https:\/\/doi.org\/10.1111\/j.1537-2995.2006.00699.x","journal-title":"Transfusion"},{"key":"5469_CR21","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1016\/j.bbmt.2014.05.003","volume":"20","author":"HK Duong","year":"2014","unstructured":"Duong HK, Savani BN, Copelan E et al (2014) Peripheral blood progenitor cell mobilization for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplan 20:1262\u20131273. https:\/\/doi.org\/10.1016\/j.bbmt.2014.05.003","journal-title":"Biol Blood Marrow Transplan"},{"key":"5469_CR22","doi-asserted-by":"publisher","unstructured":"Huang XJ, Zhu HH, Chang YJ et al The superiority of haploidentical related stem cell transplantation over chemotherapy alone as postremission treatment for patients with intermediate- or high-risk acute myeloid leukemia in first complete remission. Blood 119:5584\u20135590. https:\/\/doi.org\/10.1182\/blood-2011-11-389809","DOI":"10.1182\/blood-2011-11-389809"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05469-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05469-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05469-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T05:05:32Z","timestamp":1699679132000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05469-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,29]]},"references-count":22,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["5469"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05469-y","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,29]]},"assertion":[{"value":"1 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the ethics committee of the Affiliated People\u2019s Hospital of Ningbo University and conducted according to the Declaration of Helsinki. Written informed consent was obtained from all donors and patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}